Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Apr 16, 2021 8:49am
147 Views
Post# 33009702

RE:RE:RE:RE:RE:PMN wishes from three weeks ago..

RE:RE:RE:RE:RE:PMN wishes from three weeks ago..

I think # 2 is the key to move forward and upward. The talk has been for many years that active discussions were underway, it's time to show the fruits and either sale or create a joint venture in one or several of the other products that PMN has in the books . That would prevent dilution and bring new money into the company . It's pointless to own a bunch of great products if they just seat on the shelves 


  • Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data;



G1945V wrote: The long and short of it....... Clinical Trial....... Clinical Trial......Clinical Trial. 

The new investors need to put up more cash and get things going if their goal is to list PMN on Nasdaq. 


G1945V

 

<< Previous
Bullboard Posts
Next >>